NCT02507336View on ClinicalTrials.gov

Long-Term Followup and/or Thalidomide Maintenance Therapy for Patients Enrolled on Clinical Trial 20030165

PHASE2CompletedINTERVENTIONAL
Enrollment

2

Participants

Timeline

Start Date

November 24, 2015

Primary Completion Date

August 2, 2023

Study Completion Date

August 2, 2023

Conditions
Mantle Cell LymphomaNon-Hodgkin's Lymphoma
Interventions
DRUG

Thalidomide

100-300 mg capsule taken by mouth once daily.

Trial Locations (1)

33136

University of Miami, Miami

All Listed Sponsors
lead

University of Miami

OTHER

NCT02507336 - Long-Term Followup and/or Thalidomide Maintenance Therapy for Patients Enrolled on Clinical Trial 20030165 | Biotech Hunter | Biotech Hunter